Study: New drug prevents cytomegalovirus in stem cell transplant patients

09/25/2013 | Medscape (free registration)

A new oral antiviral drug that contains cidofovir proved effective in preventing cytomegalovirus infection in patients who had allogeneic hematopoietic cell transplants. A Phase II study published in the New England Journal of Medicine found that 10% of patients treated with CMX001 reported CMV incidence, compared with 37% in a placebo group.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN